CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a report published on Sunday morning. The firm issued a sell rating on the stock.

CEL-SCI Trading Down 8.3 %

Shares of CEL-SCI stock opened at $0.19 on Friday. CEL-SCI has a 1 year low of $0.18 and a 1 year high of $2.39. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09. The business has a 50 day moving average price of $0.32 and a 200 day moving average price of $0.57. The company has a market capitalization of $15.33 million, a P/E ratio of -0.40 and a beta of 0.95.

Institutional Trading of CEL-SCI

An institutional investor recently raised its position in CEL-SCI stock. Thoroughbred Financial Services LLC grew its position in shares of CEL-SCI Co. (NYSE:CVM) by 40.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the period. Thoroughbred Financial Services LLC owned 0.26% of CEL-SCI worth $76,000 at the end of the most recent quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.